Data demonstrate potential of Blenrep (belantamab mafodotin-blmf) in combination with standard of care therapies in patients with newly diagnosed and relapsed/refractory multiple myeloma
GlaxoSmithKline plc moment blazoned 11 objectifications on Blenrep (belantamab mafodotin-blmf) will be presented at the forthcoming American Society of Hematology (ASH) Annual Meeting and Exposition, to be hosted in Atlanta, Georgia, US and nearly from 11-14 December 2021. Donations include updates from the DREAMM ( DRiving Excellence in Approaches to Multiple Myeloma) clinical trial programme and two cooperative studies that will demonstrate the eventuality of belantamab mafodotin, a first-in- classanti-BCMA (B- cell development antigen) remedy, in multiple myeloma.
Crucial donations at ASH include results from trials of belantamab mafodotin in combination with standard curatives in cases with recently diagnosed and regressed/ refractory multiple myeloma, including
.
DREAMM-9 trial ( bill# 2738) pressing issues of a quadruplet combination treatment authority of belantamab mafodotin with bortezomib, lenalidomide and dexamethasone in transplant-ineligible cases with recently diagnosed multiple myeloma.
BelaRd ( bill# 2736), a trial being led by the Hellenic Society of Hematology in collaboration with GSK, assessing belantamab mafodotin in combination with lenalidomide and dexamethasone in cases with transplant-ineligible recently diagnosed multiple myeloma.
ALGONQUIN ( bill# 1653), a trial being led by the Canadian Myeloma Research Group in collaboration with GSK, assessing the combination of belantamab mafodotin with pomalidomide and dexamethasone (PomDex) in regressed/ refractory cases who were preliminarily treated with two or further previous lines of treatment that must have included lenalidomide and a proteasome asset. Streamlined results being presented at ASH will demonstrate the efficacity and safety of belantamab mafodotin plus PomDex and inform dosing for the part two expansion phase of the trial.
As part of GSK’s ongoing commitment to the multiple myeloma community, several real- world studies assessing unmet requirements and use of belantamab mafodotin will also be presented.
Blenrep is ananti-BCMA (B- cell development antigen) treatment that entered accelerated and tentative blessings in the US and EU, independently, for adult cases with regressed/ refractory multiple myeloma who have entered at least four previous curatives, including ananti-CD38 antibody, a proteasome asset, and an immunomodulatory agent.
Full list of belantamab mafodotin DREAMM trials and analyses
| Abstract Name | Presenter | Presentation Details |
| DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma | S. Usmani | Poster #2738 |
| Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14 | M. Hultcrantz | Poster #1645 |
| Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin? | R. Popat | Poster #2746 |
| DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin plus Inducible T cell Co-Stimulator Agonist (ICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma | N. Callander | Oral #897 |
Belantamab mafodotin GSK supported collaborative studies
| Abstract Name | Presenter | Presentation Details |
| Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) | S. Trudel | Poster #1653 |
| A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma | E. Terpos | Poster #2736 |
Multiple myeloma real-world assessments
| Abstract Name | Presenter | Presentation Details |
| A Retrospective Database Analysis of Treatment Pathways in US Medicare Patients with Multiple Myeloma and Prior Exposure to Daratumumab, an Immunomodulatory Agent, and a Proteasome Inhibitor | N. Boytsov | Poster #4019 |
| Current Clinical Practice and Decision-Making in Multiple Myeloma Treatment in the United States of America: A Real-World Survey | N. Boytsov | Poster #3001 |
| Treatment Patterns and Outcomes of Patients with Double-Class Refractory or Triple-Class Refractory Multiple Myeloma: A Retrospective US Electronic Health Record Database Study | F. Wang | Poster #2705 |
| A Retrospective Database Analysis of Treatment Pathways in US Medicare Patients with Multiple Myeloma Following Sequential Treatment with Lenalidomide and a Proteasome Inhibitor | N. Boytsov | ePublication |
| Real-World Assessment of Prior Treatment Patterns in Patients Receiving Belantamab Mafodotin Using A Longitudinal Pharmacy and Medical Open-Source Claims Database | N. Boytsov | ePublication |
GSK pipeline trial
| Abstract Name | Presenter | Presentation Details |
| Safety and Efficacy of Letetresgene Autoleucel (lete-cel; GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma | T. Nishihori | Poster #3865 |
About multiple myeloma
Multiple myeloma is the second most common blood cancer in the US and is generally considered treatable, but not curable. [1],[2] In the US, more than 32,000 people are estimated to be diagnosed with multiple myeloma this year and nearly 13,000 people will die from the disease. [3] Research into new therapies is needed as multiple myeloma commonly becomes refractory to available treatments.
About B- cell development antigen (BCMA)
The normal function of BCMA is to promote tube cell survival by transduction of signals from two known ligands, BAFF (B- cell cranking factor) and APRIL (a proliferation- converting ligand). This pathway has been shown to be important for myeloma cell growth and survival. BCMA expression is limited to B cells at after stages of development. BCMA is expressed at varying situations in myeloma cases and BCMA membrane expression is widely detected in myeloma cell lines.
GSK in Oncology
GSK is concentrated on maximising patient survival through transformational drugs. GSK’s channel is concentrated on immuno-oncology, cell remedy, tumour cell targeting curatives and synthetic lethality. Our thing is to achieve a sustainable inflow of new treatments grounded on a diversified portfolio of investigational drugs utilising modalities similar as small motes, antibodies, antibody- medicine conjugates and cell remedy, either alone or in combination.
About GSK
GSK is a wisdom- led global healthcare company. We’re a wisdom- led global healthcare company with a special purpose to ameliorate the quality of mortal life by helping people do more, feel more, live longer.
Source link: https://www.gsk.com/
